The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00633256|
Recruitment Status : Completed
First Posted : March 11, 2008
Results First Posted : April 11, 2012
Last Update Posted : April 11, 2012
A total of 20 subjects will participate in this four week, between groups, double-blind, placebo controlled study. Subjects will participate in two experimental sessions separated by approximately one week. Subjects will be randomized to receive either 50 mg cycloserine or placebo combined with cue exposure. Several physiological and subjective outcome measures (e.g., heart rate, blood pressure, galvanic skin response) will be obtained during the sessions. Experimental sessions will last approximately 4.5 hours with follow-up sessions lasting approximately thirty minutes. Our aims are:
To examine the effect of cycloserine vs. placebo on extinction of smoking cue reactivity in overnight abstinent smokers. Reactivity to smoking cues will be captured with self-report smoking urges and physiological measures (heart rate, blood pressure, and skin conductance).
We hypothesize that cycloserine, relative to placebo, will facilitate extinction of smoking cue reactivity.
- To examine the effect of cycloserine vs. placebo when combined with two 4.5 hour laboratory cue exposure training sessions, on smoking behavior in smokers. Smoking behavior will be measured with self-report smoking and saliva cotinine levels.
- To examine the effect of cycloserine vs. placebo on memory performance in nicotine dependent smokers. Memory performance will be measured with verbal learning, recognition and recall tasks.
4) To examine the safety and tolerability of cycloserine treatment in smokers. We hypothesize that cycloserine will be well tolerated by smokers.
|Condition or disease||Intervention/treatment||Phase|
|Smoking||Drug: Cycloserine Drug: Placebo||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||20 participants|
|Intervention Model:||Factorial Assignment|
|Masking:||Triple (Participant, Care Provider, Investigator)|
|Official Title:||The Effect of Cycloserine on Smoking Behavior in Nicotine Dependent Smokers.|
|Study Start Date :||December 2006|
|Actual Primary Completion Date :||February 2008|
|Actual Study Completion Date :||February 2008|
50 mg cycloserine
50 mg Cycloserine given in two separate experimental sessions separated by approximately one week.
Sham Comparator: Placebo
Matched placebo for subjects randomized to placebo arm. Given in two experimental sessions separated by approximately one week.
- Cigarettes Smoked Per Day [ Time Frame: 1 week follow-up ]The number of cigarettes smoked per day at the 1 week follow up time point.
- Cigarettes Smoked Per Day [ Time Frame: 4 Week Followup ]The number of cigarettes smoked per day at the 4-week follow up timepoint.
- Urinary Cotinine Level [ Time Frame: 4 Week Follow-up Timepoint ]Urinary Cotinine level at the 4-week follow up timepoint
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00633256
|United States, Connecticut|
|West Haven VA|
|West Haven, Connecticut, United States, 06516|
|Principal Investigator:||James Poling, Ph.D.||Yale University|